Severe COVID-19 Treatment Using Hypoxic-Mesenchymal Stem Cell Secretome: A Case Report
- 10.2991/ahsr.k.211130.049How to use a DOI?
- Covid-19; Cytokine storm; Secretome-Mesenchymal Stem Cell
COVID-19 (SARS COV-2) has a serious adverse effect in the form of Acute Respiratory Distress Syndrome (ARDS) caused by a hyper-inflammation event (‘cytokine storm’) that causes damage to the lung tissue. Previous studies have shown a link between disease severity and excessive elevation of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6). This discovery is substantiated by the plasma cytokine levels found in the majority of patients suffering from severe COVID-19 with extensive lung damage.
Recently, mesenchymal stem cells (MSCs) have shown their potency in combating the cytokine storm due to their immune-modulatory, anti-inflammation, and paracrine effects. MSCs cultured under hypoxic conditions may increase the activity of solutes known as Secretome-MSCs (S-MSCs), such as interleukin 10 (IL-10), and transforming growth factor beta (TGF-β), which are considered as principal contributing factors in reducing inflammation. In addition, they can also increase the expression of growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) that accelerate the repair of the lung injury.
In this case report, we report an effective therapy to control the COVID-19 cytokine storm that regenerates damaged lungs. A severely ill COVID-19 patient with comorbidities suffered ARDS. Standard therapy was given with no improvement. Secretome-MSCs administration was suggested. A total of 7 vials were injected in the patient via an intramuscular route. Two weeks after the last dose was administered, the patient’s condition significantly improved.
Current clinical findings show the curative prospect of secretome-MSC in the therapy of COVID-19 related ARDS.
- © 2021 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article under the CC BY-NC license.
Cite this article
TY - CONF AU - Siufui Hendrawan AU - Sandy Qlintang AU - Ronald Winardi Kartika AU - Vera Kurniawati AU - David Victorious Lukas PY - 2021 DA - 2021/12/01 TI - Severe COVID-19 Treatment Using Hypoxic-Mesenchymal Stem Cell Secretome: A Case Report BT - Proceedings of the 1st Tarumanagara International Conference on Medicine and Health (TICMIH 2021) PB - Atlantis Press SP - 290 EP - 295 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.211130.049 DO - 10.2991/ahsr.k.211130.049 ID - Hendrawan2021 ER -